S. Korea’s Binex invests in CAR-T therapy developer PeproMene Bio in US – pulse
pulse |
S. Korea's Binex invests in CAR–T therapy developer PeproMene Bio in US
pulse Binex Co., South Korea's biomedicines developer and contract manufacturing organization (CMO), has invested $10 million in PeproMene Bio Inc., a U.S.-based developer of novel immune-oncology therapies such as chimeric antigen receptor T cell (CAR-T … |
